In this edition we mark the sad birthday of 5-year-old Ariel Bibas, the little redhead being held by Hamas with his baby brother and parents. We also want you to know about the courageous stand taken by Ayelet Samerano against the UNWRA secretary-general in Lausanne.
Read about how long can a hostage survive in captivity, about Turkey in NATO, the threats to Israel from Iran and Hezbollah and what the IDF says might happen.
Semiconductor Today reported today that ColorChip's recent $45 million round of financing is already showing results with ColorChip having begun production of 100G QSFP28 10km transceivers.
In the last few years, the Internet of Things (IoT) has progressed from a fascinating vision, to a must have asset for cost and operational efficiency. In healthcare, wireless technologies are allowing doctors to monitor patients from anywhere at any time.
YOKNEAM ILIT, Israel and MARLBOROUGH, MA – ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), the leading global exoskeleton developer and manufacturer, today announced that the Company sold its 100th personal system this summer, a major milestone indicating growing adoption of personal use of exoskeletons. The Company has also sold more than 150 systems to rehabilitation centers, which are certified by the ReWalk Worldwide Training Standards that train patients for home and community use, and are key to enabling the growth of personal unit sales.
The ReWalk Personal Systems cover a diverse set of end users and geographies. The Company has placed systems across North America, Europe, Asia, Australia, and New Zealand—spanning more than a dozen countries in total. ReWalk Personal systems are being utilized in the homes and communities of law enforcement officers, veterans of the U.S. and other national armed forces, and men and women across a host of professions spanning all ages, races and ethnicities.
"This milestone symbolizes a new era for ReWalk. More public and private insurers are willing to procure and reimburse systems, the technology is evolving at a rapid pace, and there is a growing wealth of clinical evidence outlining the benefits of the technology to the health and well-being of the user," said ReWalk Robotics CEO Larry Jasinski. "We are proud to have passed the 100 personal system mark and continue to work diligently to provide this technology to all eligible users."
"My neurologist told me almost nine years ago that I would never walk again after a debilitating spinal stroke paralyzed me from the waist down," said Rick Batty, a Madison, WI ReWalker. "From that moment on, my mission in life was to stand and walk again — and ReWalk made that happen. The technology also helped me achieve a dramatic turnaround in my everyday health, increasing my upper-body strength and flexibility, and I continue to experience improvements with regular use."
The ReWalk Robotics Personal 6.0 is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with spinal cord injury to stand upright and walk. ReWalk is the first exoskeleton system to receive FDA clearance for use in the home as well as in the rehabilitation setting.
For more information, please visit: www.rewalk.com
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. Our mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit http://www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future performance and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and to expand to new markets; ReWalk's ability to maintain and grow its reputation and to achieve and maintain market acceptance of its products; ReWalk's ability to achieve reimbursement from third-party payors for its products; ReWalk's expectations as to its clinical research program and clinical results; ReWalk's expectations as to the results of, and the Food and Drug Administration's potential regulatory actions with respect to, ReWalk's mandatory post-market 522 surveillance study; ReWalk's ability to repay its secured indebtedness; ReWalk's ability to improve its products and develop new products; ReWalk's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's ability to secure capital from its at-the-market equity distribution program based on the price range of its ordinary shares and conditions in the financial markets; ReWalk's ability to maintain relationships with existing customers and develop relationships with new customers; and other factors discussed under the heading "Risk Factors" in ReWalk's Annual Report on Form 10-K for the year endedDecember 31, 2015 filed with the U.S. Securities and Exchange Commission and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
YOKNEAM, Israel, September 8, 2016
Innovative device for parent vessel protection during intracranial aneurysm treatment impacting lives around the world
Rapid Medical, a company focused on the development of neurovascular interventional devices, announced today that the Comaneci Adjustable Remodeling Mesh has exceeded 500 successfully treated aneurysms worldwide. This milestone comes only two years after Rapid Medical launched the device in Europe.
The Comaneci is the first-ever adjustable, fully-visible remodeling device. It is intended to provide temporary assistance for coil embolization of intracranial aneurysms. It integrates the advantages of existing adjuvant devices without the risk of parent vessel occlusion during coiling procedure or the need for long-term antiplatelet medication in case of permanent stenting.
“With traditional balloon remodeling techniques, preserving constant flow into intracranial arteries is impossible. The availability of a fully-visible device that permits constant flow during the procedure was previously non-existent,” said Prof. Dr. Luca Remonda, Head of Neuroradiology, at Kantonsspital Aarau, Switzerland. “The Comaneci has become a standard tool in our practice and many of our patients have experienced its benefits.”
The Comaneci uses Rapid Medical’s FlexiBraid technology, a unique and proprietary braiding capability that allows the first fully-visible, controllable device that can be adjusted by the physician to perfectly fit the dimensions of parent vessels and the aneurysm neck.
Three versions of the device are currently available; each designed to treat aneurysms in different anatomical locations. The Comaneci and Comaneci Petit versions are delivered through a microcatheter with an internal diameter of 0.021″ and the Comaneci 17 version through a micorcatheter with an internal diameter of 0.0165″.
“We are very pleased with the rapid adoption of the Comaneci device, which is becoming a preferred tool in neurovascular practice,” said Eitan Havis, VP of Sales and Marketing. “We believe the combination of adjustability, visibility and compliance offered by the Comaneci is a critical part in successful aneurysm treatment.”
The Comaneci family of devices are available for sale in Europe and Israel. Rapid Medical plans to launch the Comaneci in additional regions in the coming months.
About Rapid Medical
Rapid Medical is the developer of game-changing devices for endovascular treatments. This includes TIGERTRIEVER, the first-ever controllable, fully-visible retrievable stent, and Pele, a large lumen distal access catheter. TIGERTRIEVER, Comaneci, and Pele are CE marked for use in Europe. More information is available at http://www.rapid-medical.com.
Contact:
Eitan Havis, VP of Sales and Marketing
Rapid Medical
eitan@rapid-medical.com
+972-72-250-3331
Eindhoven University of Technology Selects Zadara Storage to Support 300+ VMware Servers TU/e replaces CapEx storage with elastic, scalable OpEx-based Zadara Storage-as-a-Service IRVINE, CA – August 30, 2016 –
Zadara™ Storage, the award-winning provider of enterprise-class storage-as-a-service (STaaS) today announced that Eindhoven University of Technology (TU/e) has chosen the Zadara VPSA storage array architecture to support their TU/e campus and advanced research teams. By leveraging the Zadara Storage VPSA On-Premise-as-a-Service (OPaaS) solution, TU/e has been able to enjoy the benefits of a pure OpEx model supporting their internal clients, while keeping their data on-site within their data center.
Eindhoven University of Technology Selects Zadara Storage to Support 300+ VMware Servers TU/e replaces CapEx storage with elastic, scalable OpEx-based Zadara Storage-as-a-Service IRVINE, CA – August 30, 2016 –
Zadara™ Storage, the award-winning provider of enterprise-class storage-as-a-service (STaaS) today announced that Eindhoven University of Technology (TU/e) has chosen the Zadara VPSA storage array architecture to support their TU/e campus and advanced research teams. By leveraging the Zadara Storage VPSA On-Premise-as-a-Service (OPaaS) solution, TU/e has been able to enjoy the benefits of a pure OpEx model supporting their internal clients, while keeping their data on-site within their data center.
The Eindhoven University of Technology is located in the center of Eindhoven, the Netherlands and is currently home to about 255 professors, 10,100 students, 243 Ph.D. graduates, 1,250 foreign students and 3,145 regular employees. Yearly, the Eindhoven University of Technology produces almost 3,000 scientific publications, 140 PhD-awards, and 40 patents. As the storage needs of the university grew, each department procured, deployed and managed their own storage resources.
The inefficiencies of having separate storage arrays in data centers throughout the TU/e campus became apparent. Each storage array needed to be managed and maintained separately. Devices were over-provisioned with excess unused capacity. A change was clearly needed. After completing their due-diligence by evaluating proposals from each of the leading storage providers, TU/e chose Zadara as their storage partner. As Huub De Hesselle, Strategy & Policy Advisor for TU/e described, “once we reviewed the solutions in our tender, Zadara Storage offered the best fit.”
The Zadara Storage On-Premise-as-a-Service solution offered the following key benefits:
“Our data storage is the base of operations for nearly every application we run. It was critical that we chose the right storage solution,” said Thieu Mennen, Manager Back Office at TU/e. “By centralizing our storage services on Zadara Storage, we have increased our agility, reduced cost and improved data security.” “Zadara has proven to be a valuable partner throughout the deployment process by accommodating our unique needs and helping us define specific solutions to our challenges,” said Huub De Hesselle, Strategy & Policy Advisor at TU/e. “We were pleased to find a partner who has gone above and beyond our basic requirements.” “TU/e is an excellent example of an organization who has recognized the benefits of OpEx-based, Storage-as-a-Service,” said Dani Naor, vice president, international sales at Zadara Storage. “They were able to deploy an on-premise solution, providing scalable, elastic storage services to their internal clients and also protect against unexpected disasters with remote mirroring.” Click to Tweet: Eindhoven University of Technology Selects @ZadaraStorage to Support 300+ @VMware Servers – http://bit.ly/EindhovenSelectsZadara
Zadara Storage offers enterprise Storage-as-a-Service (STaaS) through the award-winning Zadara Storage Cloud. It can be deployed at any location (cloud, on-premise or hybrid), supporting any data type (block, file and object) and connecting to any protocol (FC, iSCSI, iSER, NFS, CIFS, S3/ Swift).
The VPSA™ service provides enterprise SAN and NAS while the ZIOS™ service delivers private object storage. Zadara provides resource isolation, exceptional data security, and management control. Zadara is available via OPaaS (On-Premise-as-a-Service) and through a variety of partners including Amazon Web Services (AWS), Microsoft Azure and others.
Sarah Falulner of Massdevice.com reported that Syneron Candela severed its ties with Olympic swimmer Ryan Lochte, who was a spokesman for the aesthetic device company’s Gentle Hair Removal brand.
The patent for Hardware-assisted application checkpointing and restoring was granted yesterday and is assigned to Intel. Igor worked with a colleague from Bangalore on the invention.
According to the article, this is a solution that can provide upright mobility for 90% of the wheelchair population. The price is expected to be in the middle of the price range for high-end powered wheelchairs.
